An updated systematic review of the pharmacology of silymarin

Forschende Komplementarmedizin

Volumn 14, Issue 2, 2007, Pages 70-80

  Saller, R ^a   Melzer, J ^a   Reichling, J ^b   Brignoli, R ^c   Meier, R ^d  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Tradyser GmbH   (Switzerland)

^d UNIVERSITY OF BASEL   (Switzerland)

Author keywords

ABC transporters; Herbal drug; Milk thistle; Nitric oxide synthase; Phytopharmacology; Scavenger; Silibinin; Silymarin; TNF ; UV induced damage

Indexed keywords

ABC TRANSPORTER; AMIODARONE; ANTIOXIDANT; BILE SALT; CISPLATIN; COLLAGEN; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLOSPORIN; DOXORUBICIN; FUMONISIN B1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; ISOSILYBIN A; ISOSILYBIN B; LIPOXYGENASE; METHOTREXATE; ORGANIC ANION TRANSPORTER; PARACETAMOL; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53; QUERCETIN DERIVATIVE; REACTIVE OXYGEN METABOLITE; SELECTIN; SILIBININ; SILIBININ PHOSPHATIDYLCHOLINE COMPLEX; SILYMARIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ANTIOXIDANT ACTIVITY; CELL MEMBRANE; COLLAGEN SYNTHESIS; COLON CARCINOMA; DATA BASE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; HEPATITIS VIRUS; HUMAN; IMMUNOMODULATION; LIVER INJURY; NONHUMAN; OVARY CANCER; PROSTATE CARCINOMA; REVIEW; SKIN PAPILLOMA; SKIN PROTECTION; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; TONGUE CARCINOMA; TUMOR SUPPRESSOR GENE; ULTRAVIOLET IRRADIATION; VIRUS REPLICATION; WORKING MEMORY;

ANIMALS; ANTIOXIDANTS; BIOLOGICAL TRANSPORT; CELL MEMBRANE; HUMANS; LIVER; MILK THISTLE; PHYTOTHERAPY; PROTECTIVE AGENTS; SILYMARIN; TREATMENT OUTCOME;

EID: 34247536407     PISSN: 16614119     EISSN: 16614127     Source Type: Journal    
DOI: 10.1159/000100581     Document Type: Review

References (100)

1. American Botanical Council (ABC) (ed): The ABC Clinical Guide to Herbs. Austin, TX, American Botanical Council, 2003.
2. Frömming KH, Saller R, Wachter W: [Silymarincontaining phytopharmaceuticals - biopharmacy as an essential therapeutic quality criterion] Z Arztl Fortbild Qualitatssich 1999;93:VI-XI.
3. Leng-Peschlow E, Strenge-Hesse A: Die Mariendistel (Silybum marianum) und Silymarin als Lebertherapeutikum. Z Phytother 1991;12:162-164.
4. Jacob SW, Herschler R: Pharmacology of DMSO. Cryobiology 1986;23(1):14-27.
5. Mulrow C, Lawrence V, Jacobs B, Dennehy C, Sapp J, Gilbert Ramirez RN, Aguilar C, Montgomery K, Morbidoni L, Moore Arterburn J, Chiquette E, Harris M, Mullins D, Vickers A, Flora K: Milk thistle: effects on liver disease and cirrhosis and clinical adverse effects. Evidence Report/Technology Assessment No. 21 (Contract 290-97-0012) AHRQ Publication No. 01-E025. Rockville, MD, Agency for Healthcare Research and Quality, October 2000.
6. Fraschini F, Demartini G, Esposti D: Pharmacology of silymarin. Clin Drug Invest 2002;22(1):51-65.
7. Mizuno N, Niwa T, Yotsumoto Y, Sugiyama Y: Impact of drug transporter studies on drug discovery and development. Pharmacol Rev 2003;55:425-461.
8. Fehrenbach T, Cui Y, Faulstich H, Keppler D: Characterization of the transport of the bicyclic peptide phalloidin by human hepatic transport proteins. Naunyn Schmiedebergs Arch Pharmacol 2003;368(5):415-420.
9. Munter K, Mayer D, Faulstich H: Characterization of a transporting system in rat hepatocytes. Studies with competitive and non-competitive inhibitors of phalloidin transport. Biochim Biophys Acta 1986;860(1):91-98.
10. Šebestian J, Sěbestianová SB, Moulisová V, Jegorov A: Membrane transport without receptors? The role of cyclosporines and silymarines structures for their interactions with lipids of hepatocyte plasma membrane. Mater Struct 2004;11:15-17.
11. Faulstich H, Jahn W, Wieland T: Silybin inhibition of amatoxin uptake in the perfused rat liver. Arzneimittelforschung 1980;30:452-454.
12. Hugentobler G, Kroncke KD, Fricker G, Kurz G, Meier PJ: Carrier mediated uptake of alpha amanitin in rat liver. 18th Annual Meeting of the Union of Swiss Societies of experimental biology, Basel, Switzerland, Mar. 20-21, 1986. Experientia Basel 1986;42:645.
13. Zhang S, Morris ME: Effects of the flavonoids biochanin a, morin, phloretin, and silymarin on p-glycoprotein-mediated transport. J Pharmacol Exp Ther 2003;30(3):1258-1267.
14. Chlopcikova S, Psotova J, Miketova P, Simanek V: Chemoprotective effect of plant phenolics against anthracycline- induced toxicity on rat cardiomyocytes. Part I. Silymarin and its flavonolignans. Phytother Res 2004;18(2):107-110.
15. Zhang S, Yang X, Morris ME: Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol Pharmacol 2004;65:1208-1216.
16. Tyagi AK, Agarwal C, Chan DC, Agarwal R: Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells. Oncol Rep 2004;11(2):493-499.
17. Crocenzi FA, Basiglio CL, Perez LM, Portesio MS, Pozzi EJ, Roma MG: Silibinin prevents cholestasisassociated retrieval of the bile salt export pump, Bsep, in isolated rat hepatocyte couplets: Possible involvement of cAMP. Biochem Pharmacol 2005;69(7):1113-1120.
18. Milkiewicz P, Roma MG, Elias E, Coleman R: Review: Pathobiology and experimental therapeutics in hepatocellular cholestasis: lessons from the hepatocyte couplet model. Clin Sci 2002;102:603-614.
19. Muriel P, Moreno MG: Effects of silymarin and vitamins E and C on liver damage induced by prolonged biliary obstruction in the rat. Basic Clin Pharmacol Toxicol 2004;94(2):99-104.
20. El-Bahay C, Gerber E, Horbach M, Tran-Thi QH, Rohrdanz E, Kahl R: Influence of tumor necrosis factor-alpha and silibin on the cytotoxic action of alpha-amanitin in rat hepatocyte culture. Toxicol Appl Pharmacol 1999;158:253-260.
21. Chovolou Y, Watjen W, Kampkotter A, Kahl R: Resistance to Tumor Necrosis Factor-α (TNF- α)-induced apoptosis in rat hepatoma cells expressing TNF- α is linked to low antioxidant enzyme expression. J Biol Chem 2003;278(32):29626-29632.
22. Quanren He, Jiyoung Kim, Raghubir PS: Silymarin protects against liver damage in BALB/c mice exposed to Fumonisin B1 despite increasing accumulation of free sphingoid bases. Toxicol Sci 2004;80:335-342.
23. Wang MJ, Lin WW, Chen HL, Chang YH, Ou HC, Kuo JS, Hong JS, Jeng KC: Silymarin protects dopaminergic neurons against lipopolysaccharide-induced neurotoxicity by inhibiting microglia activation. Eur J Neurosci 2002;16(11):2103-2112.
24. Kang JS, Park SK, Yang KH, Kim HM: Silymarin inhibits TNF-alpha-induced expression of adhesion molecules in human umbilical vein endothelial cells. FEBS Lett 2003;550(1-3):89-93.
25. Deak G, Muzes G, Lang I, Nekam K, Gonzalez-Cabello R, Gergely P, Feher J: Effects of two bioflavonoids on certain cellular immune reactions in vitro. Acta Physiol Hung 1990;76:113-121.
26. Schumann J, Prockl J, Kiemer AK, Vollmar AM, Bang R, Tiegs G: Silibinin protects mice from T cell-dependent liver injury. J Hepatol 2003;39(3):333-340.
27. Mira L, Silva M, Manso CF: Scavenging of reactive oxygen species by silibinin dihemisuccinate. Biochem Pharmacol 1994;48:753-759.
28. Feher J, Lang I, Nekam K, Muzes G, Deak G: Effect of free radical scavengers on superoxide dismutase (SOD) enzyme in patients with alcoholic cirrhosis. Acta Med Hung 1988;45:265-276.
29. Miguez MP, Anundi I, Sainz-Pardo LA, Lindros KO: Hepatoprotective mechanism of silymarin: no evidence for involvement of cytochrome P450 2E1. Chem Biol Interact 1994;91:51-63.
30. Neuman MG, Cameron RG, Haber JA, Katz GG, Malkiewicz IM, Shear NH: Inducers of cytochrome P450 2E1 enhance methotrexate-induced hepatocytoxicity. Clin Biochem 1999;32:519-536.
31. van Pelt JF, Verslype C, Crabbe T, Zaman Z, Fevery J: Primary human hepatocytes are protected against prolonged and repeated exposure to ethanol by silibinin-dihemisuccinate. Alcohol Alcohol 2003;38(5):411-414.
32. Venkataramanan R, Ramachandran V, Komoroski BJ, Zhang S, Schiff PL, Strom SC: Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures. Drug Metab Dispos 2000;28(11):1270-1273.
33. Busby A, La Grange L, Edwards J, King J: The use of a silymarin/phospholipid compound as a fetoprotectant from ethanol-induced behavioral deficits. J Herb Pharmacother 2002;2(1):39-47.
34. Neese S, La Grange L, Trujillo E, Romero D: The effects of ethanol and silymarin treatment during gestation on spatial working memory. BMC Complement Altern Med 2004;4(1):4.
35. Karimi G, Ramezani M, Tahoonian Z: Cisplatin nephrotoxicity and protection by milk thistle extract in rats. Evid Based Complement Alternat Med 2005;2(3):383-386.
36. Gupta YK, Sharma M, Chaudhary G: Pyrogallol-induced hepatotoxicity in rats: a model to evaluate antioxidant hepatoprotective agents. Methods Find Exp Clin Pharmacol 2002;24(8):497-500.
37. Wenzel S, Stolte H, Soose M: Effects of silibinin and antioxidants on high glucose-induced alterations of fibronectin turnover in human mesangial cell cultures. J Pharmacol Exp Ther 1996;279:1520-1526.
38. Agoston M, Orsi F, Feher E, Hagymasi K, Orosz Z, Blazovics A, Feher J, Vereckei A: Silymarin and vitamin E reduce amiodarone-induced lysosomal phospholipidosis in rats. Toxicology 2003;190(3):231-241.
39. Vereckei A, Zipes DP, Besch H: Combined amiodarone and silymarin treatment, but not amiodarone alone, prevents sustained atrial flutter in dogs. J Cardiovasc Electrophysiol 2003;14(8):861-867.
40. Soto CP, Perez BL, Favari LP, Reyes JL: Prevention of alloxan-induced diabetes mellitus in the rat by silymarin. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1998;119:125-129.
41. Soto C, Recoba R, Barron H, Alvarez C, Favari L: Silymarin increases antioxidant enzymes in alloxan-induced diabetes in rat pancreas. Comp Biochem Physiol C Toxicol Pharmacol 2003;136(3):205-212.
42. Soto C, Mena R, Luna J, Cerbon M, Larrieta E, Vital P, Uria E, Sanchez M, Recoba R, Barron H, Favari L, Lara A: Silymarin induces recovery of pancreatic function after alloxan damage in rats. Life Sci 2004;75(18):2167-2180.
43. von Schonfeld J, Weisbrod B, Muller MK: Silibinin, a plant extract with antioxidant and membrane stabilizing properties, protects exocrine pancreas from cyclosporin A toxicity. Cell Mol Life Sci 1997;53:917-920.
44. Gorio A, Donadoni ML, Finco C, Di Giulio AM: Endogenous mono-ADP-ribosylation in retina and peripheral nervous system. Effects of diabetes. Adv Exp Med Biol 1997;419:289-295.
45. Dehmlow C, Erhard J, de Groot H: Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology 1996;23:749-754.
46. Lin AY, Rui YC: [Inhibitory effect of silybin on the activity of 5-lipoxygenase of the porcine cerebral basilar artery] Zhongguo Yao Li Xue Bao 1989;10:414-418.
47. Dehmlow C, Murawski N, de Groot H: Scavenging of reactive oxygen species and inhibition of arachidonic acid metabolism by silibinin in human cells. Life Sci 1996;58:1591-1600.
48. Matsuda T, Ferreri K, Todorov I, Kuroda Y, Smith CV, Kandeel F, Mullen Y: Silymarin protects pancreatic beta-cells against cytokine-mediated toxicity: implication of c-Jun NH2-terminal kinase and janus kinase/signal transducer and activator of transcription pathways. Endocrinology 2005;146(1):175-185.
49. D'Andrea V, Perez LM, Sanchez Pozzi EJ: Inhibition of rat liver UDP-glucuronosyltransferase by silymarin and the metabolite silibinin- glucuronide. Life Sci 2005;77:683-692.
50. Sridar C, Goosen TC, Kent UM, Williams JA, Hollenberg PF: Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metab Dispos 2004;32:587-594.
51. Sonnenbichler J, Zetl I: [Mechanism of action of silibinin. V. Effect of silibinin on the synthesis of ribosomal RNA, mRNA and tRNA in rat liver in vivo] Hoppe Seylers Z Physiol Chem 1984;365(5):555-566.
52. Sonnenbichler J, Goldberg M, Hane L, Madubunyi I, Vogl S, Zetl I: Stimulatory effect of Silibinin on the DNA synthesis in partially hepatectomized rat livers: non-response in hepatoma and other malign cell lines. Biochem Pharmacol 1986;35(3):538-541.
53. Kliewer SA, Goodwin B, Willson TM: The nuclear pregnane x receptor: a key regulator of xenobiotic metabolism. Endocrine Rev 2002;23:687-702.
54. Raucy JL: Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab Dispos 2003;31:533-539.
55. Deep G, Singh RP, Agarwal C, Kroll DJ, Agarwal R: Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells: a comparison of flavanone silibinin with flavanolignan mixture silymarin. Oncogene 2006;25(7):1053-1069.
56. Kang JS, Jeon YJ, Kim HM, Han SH, Yang KH: Inhibition of inducible nitric-oxide synthase expression by silymarin in lipopolysaccharide-stimulated macrophages. J Pharmacol Exp Ther 2002;302(1):138-144.
57. Saliou C, Rihn B, Cillard J, Okamoto T, Packer L: Selective inhibition of NF-kappa B activation by the flavonoid hepatoprotector silymarin in HepG2. Evidence for different activating pathways. FEBS Lett 1998;440:8-12.
58. Lee JI, Burckart GJ: Nuclear factor kappa B: important transcription factor and therapeutic target. J Clin Pharmacol 1998;38:981-993.
59. Manna SK, Mukhopadhyay A, Van NT, Aggarwal BB: Silymarin suppresses TNF-induced activation of NF-kappa B, c-Jun N-terminal kinase, and apoptosis. J Immunol 1999;163:6800-6809.
60. Saliou C, Kitazawa M, McLaughlin L, Yang JP, Lodge JK, Tetsuka T, Iwasaki K, Cillard J, Okamoto T, Packer L: Antioxidants modulate acute solar ultraviolet radiation-induced NF- kappa-B activation in a human keratinocyte cell line. Free Radic Biol Med 1999;26:174-183.
61. Harakeh S, Jariwalla RJ: NF-kappa B-independent suppression of HIV expression by ascorbic acid. AIDS Res Hum Retroviruses 1997;13:235-239.
62. Favari L, Perez-Alvarez V: Comparative effects of colchicine and silymarin on CCl4-chronic liver damage in rats. Arch Med Res 1997;28:11-17.
63. Muriel P, Moreno MG, Hernandez Mdel C, Chavez E, Alcantar LK: Resolution of liver fibrosis in chronic CCl4 administration in the rat after discontinuation of treatment: effect of silymarin, silibinin, colchicine and trimethylcolchicinic acid. Basic Clin Pharmacol Toxicol 2005;96(5):375-380.
64. Mourelle M, Muriel P, Favari L, Franco T: Prevention of CCL4-induced liver cirrhosis by silymarin. Fundam Clin Pharmacol 1989;3:183-191.
65. Boigk G, Stroedter L, Herbst H, Waldschmidt J, Riecken EO, Schuppan D: Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology 1997;26:643-649.
66. Jia JD, Bauer M, Cho JJ, Ruehl M, Milani S, Boigk G, Riecken EO, Schuppan D: Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen alpha 1(I) and TIMP-1. J Hepatol 2001;35(3):392-398.
67. Lieber CS, Leo MA, Cao Q, Ren C, DeCarli LM: Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons. J Clin Gastroenterol 2003;37(4):336-339.
68. Johnson VJ, He Q, Osuchowski MF, Sharma RP: Physiological responses of a natural antioxidant flavonoid mixture, silymarin, in BALB/c mice: III. Silymarin inhibits T-lymphocyte function at low doses but stimulates inflammatory processes at high doses. Planta Med 2003;69(1):44-49.
69. Balmain AB, Harris CC: Carcinogenesis in mouse and human cells: parallels and paradoxes. Carcinogenesis 2000;21(3):371-377.
70. Kohno H, Tanaka T, Kawabata K, Hirose Y, Sugie S, Tsuda H, Mori H: Silymarin, a naturally occurring polyphenolic antioxidant flavonoid, inhibits azoxymethane-induced colon carcinogenesis in male F344 rats. Int J Cancer 2002;101(5):461-468.
71. Yang SH, Lin JK, Huang CJ, Chen WS, Li SY, Chiu JH: Silibinin inhibits angiogenesis via Flt-1, but not KDR, receptor up-regulation. J Surg Res 2005;128(1):140-146.
72. Yanaida Y, Kohno H, Yoshida K, Hirose Y, Yamada Y, Mori H, Tanaka T: Dietary silymarin suppresses 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in male F344 rats. Carcinogenesis 2002;23(5):787-794.
73. Kohno H, Suzuki R, Sugie S, Tsuda H, Tanaka T: Dietary supplementation with silymarin inhibits 3.2′-dimethyl-4-aminobiphenyl-induced prostate carcinogenesis in male F344 rats. Clin Cancer Res 2005;11(13):4962-4967.
74. Singh RP, Dhanalakshmi S, Tyagi AK, Chan DC, Agarwal C, Agarwal R: Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels. Cancer Res 2002;62(11):3063-3069.
75. Singh RP, Sharma G, Dhanalakshmi S, Agarwal C, Agarwal R: Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis. Cancer Epidemiol Biomarkers Prev 2003;12(9):933-939.
76. Thelen P, Jarry H, Ringert RH, Wuttke W: Silibinin down-regulates prostate epithelium-derived Ets transcription factor in LNCaP prostate cancer cells. Planta Med 2004;70(5):397-400.
77. Thelen P, Wuttke W, Jarry H, Grzmil M, Ringert RH: Inhibition of telomerase activity and secretion of prostate specific antigen by silibinin in prostate cancer cells. J Urol 2004;171(5):1934-1938.
78. Davis-Searles PR, Nakanishi Y, Kim NC, Graf TN, Oberlies NH, Wani MC, Wall ME, Agarwal R, Kroll DJ: Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells. Cancer Res 2005;65(10):4448-4457.
79. Singh RP, Agarwal R: Prostate cancer prevention by silibinin. Curr Cancer Drug Targets 2004;4(1):1-11.
80. Huang Q, Wu LJ, Tashiro S, Onodera S, Li LH, Ikejima T: Silymarin augments human cervical cancer HeLa cell apoptosis via P38/JNK MAPK pathways in serum-free medium. J Asian Nat Prod Res 2005;7(5):701-709.
81. Gallo D, Giacomelli S, Ferlini C, Raspaglio G, Apollonio P, Prislei S, Riva A, Morazzoni P, Bombardelli E, Scambia G: Antitumour activity of the silybin-phosphatidylcholine complex, IdB 1016, against human ovarian cancer. Eur J Cancer 2003;39(16):2403-2410.
82. Gaedeke J, Fels LM, Bokemeyer C, Mengs U, Stolte H, Lentzen H: Cisplatin nephrotoxicity and protection by silibinin. Nephrol Dial Transplant 1996;11(1):55-62.
83. Zima T, Kamenikova L, Janebova M, Buchar E, Crkovska J, Tesar V: The effect of silibinin on experimental cyclosporine nephrotoxicity. Ren Fail 1998;20(3):471-479.
84. Chlopcikova S, Psotova J, Miketova P, Simanek V: Chemoprotective effect of plant phenolics against anthracycline- induced toxicity on rat cardiomyocytes. Part I. Silymarin and its flavonolignans. Phytother Res 2004;18(2):107-110.
85. Kropacova K, Misurova E, Hakova H: Protective and therapeutic effect of silymarin on the development of latent liver damage. Radiats Biol Radioecol 1998;38(3):411-415.
86. Ramadan LA, Roushdy HM, Abu Senna GM, Amin NE, El-Deshw OA: Radioprotective effect of silymarin against radiation induced hepatotoxicity. Pharmacol Res 2002;45(6):447-454.
87. Singh RP, Tyagi AK, Zhao J, Agarwal R: Silymarin inhibits growth and causes regression of established skin tumors in SENCAR mice via modulation of mitogen-activated protein kinases and induction of apoptosis. Carcinogenesis 2002;23(3):499-510.
88. Gu M, Dhanalakshmi S, Singh RP, Agarwal R: Dietary feeding of silibinin prevents early biomarkers of UVB radiation-induced carcinogenesis in SKH-1 hairless mouse epidermis. Cancer Epidemiol Biomarkers Prev 2005;14(5):1344-1349.
89. Gu M, Dhanalakshmi S, Mohan S, Singh RP, Agarwal R: Silibinin inhibits ultraviolet B radiation-induced mitogenic and survival signaling, and associated biological responses in SKH-1 mouse skin. Carcinogenesis 2005;26(8):1404-1413.
90. Dhanalakshmi S, Mallikarjuna GU, Singh RP, Agarwal R: Silibinin prevents ultraviolet radiation-caused skin damages in SKH-1 hairless mice via a decrease in thymine dimer positive cells and an upregulation of p53-p21/Cip1 in epidermis. Carcinogenesis 2004;25(8):1459-1465.
91. Dhanalakshmi S, Mallikarjuna GU, Singh RP, Agarwal R: Dual efficacy of silibinin in protecting or enhancing ultraviolet B radiation-caused apoptosis in HaCaT human immortalized keratinocytes. Carcinogenesis 2004;25(1):99-106.
92. Katiyar SK: Treatment of silymarin, a plant flavonoid, prevents ultraviolet light- induced immune suppression and oxidative stress in mouse skin. Int J Oncol 2002;21(6):1213-1222.
93. Mallikarjuna G, Dhanalakshmi S, Singh RP, Agarwal C, Agarwal R: Silibinin protects against photo-carcinogenesis via modulation of cell cycle regulators, mitogen-activated protein kinases, and Akt signaling. Cancer Res 2004;64(17):6349-6356.
94. Lu YP, Lou YR, Xie JG, Peng QY, Liao J, Yang CS, Huang MT, Conney AH: Topical applications of caffeine or (-)-epigallocatechin gallate (EGCG) inhibit carcinogenesis and selectively increase apoptosis in UVB-induced skin tumors in mice. Proc Natl Acad Sci USA 2002;99(19):12455-12460.
95. Dhanalakshmi S, Agarwal C, Singh RP, Agarwal R: Silibinin up-regulates DNA-PK-dependent p53 activation to enhance UVB-induced apoptosis in mouse epithelial JB6 cells. J Biol Chem 2005;280(21):20375-20383.
96. Katiyar SK, Roy AM, Baliga MS: Silymarin induces apoptosis primarily through a p53-dependent pathway involving Bcl-2/Bax, cytochrome c release, and caspase activation. Mol Cancer Ther 2005;4(2):207-216.
97. DiPaola RS: To arrest or not to G(2)-M Cell-cycle arrest: commentary re: A. K. Tyagi et al., Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G(2)-M arrest, and apoptosis. Clin cancer res 2002;8:3512-3519.
98. Clin Cancer Res 2002;8(11):3311-3314.
99. Katiyar SK: Silymarin and skin cancer prevention: anti-inflammatory, antioxidant and immunomodulatory effects (Review). Int J Oncol 2005;26(1):169-176.
100. Saller R, Meier R, Brignoli R: The use of silymarin in the treatment of liver diseases. Drugs 2001;61:2035-2063.